Home/Filings/4/0001808805-23-000030
4//SEC Filing

Murphy Matthew B. 4

Accession 0001808805-23-000030

CIK 0001808805other

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 5:19 PM ET

Size

5.9 KB

Accession

0001808805-23-000030

Insider Transaction Report

Form 4
Period: 2023-02-27
Murphy Matthew B.
General Counsel
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-02-27+160,000160,000 total
    Exercise: $2.00Exp: 2033-02-27Common Stock (160,000 underlying)
Footnotes (1)
  • [F1]Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023.

Issuer

Nautilus Biotechnology, Inc.

CIK 0001808805

Entity typeother

Related Parties

1
  • filerCIK 0001865778

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 5:19 PM ET
Size
5.9 KB